INTRODUCTION
A better understanding of tumor growth is crucial for the clinical management of the disease since tumor size is a main staging criterion before and during radiotherapy (1) . Tumor regrowth during radiotherapy is therefore an important clinical parameter (2) ; in particular, the dose-response relationship and thus the probability of treatment benefit critically depend on the tumor growth between the fractional irradiations. To evaluate the clinical results, the surviving tumor cell fraction S after n irradiations at dose (per fraction) d in the overall treatment time t is usually described as 2 Ϫln(S) ϭ n(␣d ϩ ␤d ) Ϫ ␥t,
which depends on the tumor radiosensitivity, expressed by the parameters ␣ and ␤ according to the linear-quadratic model, and on the tumor regrowth parameter ␥ ϭ (ln 2)/ eff , with eff being the average clonogenic doubling time (3) . Until now, Eq. (1) has been the basis for radiotherapy scheduling, and it would predict the probability P of tumor control, defined as P ϭ exp(ϪcS) (4) , with c being the clonogenic number.
Previously, untreated tumor growth had usually been described by means of the Gompertz law (GL) (5) (6) (7) (8) , a nonlinear growth pattern that was proposed a long time ago in actuarial mathematics (9) . For instance, in a transplantable rat tumor, it was shown that control and regrowth curves after radiotherapy could be fitted by the same Gompertz law, provided adjustments were made for the initial lag phase and the estimated number of clonogenic cells immediately after irradiation (10) . Consequently, Gompertzian growth has also been used to describe repopulation in human tumors during fractional radiotherapy, for example (11, 12) .
However, an alternative general growth law has recently been proposed that is based on the scaling properties of the nutrient-supplying, distributive vascular network (13, 14) ; it is described as being ''universal'' since it can fit the growth patterns of most living organisms, covering more than 27 orders of magnitude in mass. This Universal law (UL) has been shown to fit many available data sets on tumors in vivo and on multicellular tumor spheroids reasonably well (15) . In this paper, we analyze these two different growth patterns in an attempt to evaluate their impact on clinical treatment regimens. Our results provide new insights into several well-known clinical observations. Up until 1956 (16) , human tumor growth was simply described as ''slow'' and ''rapid'', with no attempt for a more quantitative description (16) . A naive view would consider an exponential growth from a 10-mdiameter cell to a 1-liter tumor in about 20 doublings. On this basis, from two volumetric measurements V 1 and V 2 at different times t 1 and t 2 , a tumor doubling time (assumed to be constant) can be estimated as d ϭ (t 1 Ϫ t 2 )/(ln 2)(V 1 /V 2 ). However, several studies using animal models (5) and two very important investigations of breast and prostate cancer in humans (7, 8) showed that, far from being constant, t d changed during tumor growth; this is well described mathematically by Gompertzian growth kinetics ( 
TUMOR GROWTH LAWS
Here N(t) is the number of tumor cells and is proportional to the tumor mass; both K g and a 0 are constants, and ϭ N(0).
0 g N dt which corresponds to a specific growth rate that is proportional to ln(N).
Although it is generally considered to be a phenomenological tool only, there have been many attempts to derive the Gompertz law by more fundamental dynamics (18, 19) . For the analysis of tumor growth in patients, a single set of growth parameters is insufficient to describe the data. Tumor cells have different growth conditions and characteristics in different patients, and the variations in tumor growth in the patient population have been modeled by using a distribution of growth parameters. The data can be fitted by a log-normal distribution of the parameter K g . For example, the data of Bloom et al. on breast cancer (20) are consistent with ϭ 4.8 ϫ 10 9 , ϭ 3.1 ϫ 10
12
, a mean value of the log-normal distribution given by ln(K g ) ϭ Ϫ2.9 and a standard deviation of ln(K g ) ϭ 0.71 (7) .
A new tumor growth model has recently been proposed on the basis of the work of West et al. (13) that, regardless of the different masses and development times, suggests that many living organisms share a common growth pattern and, provided that the masses and growth times are properly rescaled, the same universal exponential curve fits ontogenic growth data for these organisms. This phenomenon is commonly attributed to basic cellular mechanisms (14) while assuming a common fractal pattern in the vascularization of the investigated taxa.
More precisely, starting from a cell number (or mass ) at birth, 
where 
In Guiot et al. (15) , we applied this growth pattern to tumors and were able to satisfactorily fit even multicellular tumor spheroids data in vitro, in addition to tumors grown in vivo and in humans (i.e., breast and prostate cancer). It is important to stress in this context that the West law corresponds to a particular choice of the two exponents characterizing the generalized von Bertalanffy model (21) that was proposed in the late 1950s to describe tumor growth. Finally we note that, contrary to the GL, the UL has never been applied to the case of irradiated tumors.
In Fig. 1 , we compare the GL and the UL for the cases of breast and prostate cancers. It is interesting to observe that, while it is delayed at the beginning, the UL curve increases faster than the GL at any time during tumor growth and therefore affects the tumor repopulation for both small tumors (T1 and T2) and advanced tumors.
According to standard clinical procedure, the treatment dose d is given at regular intervals. Let us assume for now that the surviving fraction for clonogenic cells is given by the linear-quadratic model [see Eq. (1) and discussion] and that the specific repopulation rate, , of clonogenic cells is a function of the population size ]N(t)]. Therefore, the differential equation for the irradiated system is
where is the interval between two treatments and n is the number of treatments per fraction given by time t Ն (n Ϫ 1) (6). For exponential growth, i.e. constant rate [N(t)] ϭ ␥ ϭ (ln 2)/T, one obtains Eq. (1) with eff ϭ T, the doubling time of the exponential law.
For both Gompertz and Universal laws, a more detailed analysis (see the Appendix) is needed to evaluate the difference between the two growth patterns with regard to the surviving fraction S after a realistic radiation treatment. As reference values for tumor radiosensitivity in the case of breast cancer, we assumed ␣ ϭ 0.3 Gy Ϫ1 and ␣/␤ ϭ 10 Gy and then computed the tumor control probability P (corresponding to the estimated values of S).
In addition to standard treatment (up to 70 Gy with daily doses of 2 Gy), we also investigated some non-standard treatment schedules recently proposed in the clinical literature. In particular, we considered (a) hyperfractionation (three daily doses of 0.8 Gy, for a total of 60 Gy over 4 weeks), (b) hypofractionation (5 Gy ϫ 5 days, for a total dose of 25 Gy in 1 week), and (c) CHART (1.5 Gy three times a day, for a total dose of 54 Gy).
RESULTS
After the initial phase, the ln(S) that results from using the UL can be reduced by adjusting the radiotherapy dose and interval but cannot be further reduced by increasing the number of treatments. This is distinctively different in the case of the Gompertz law, where the final surviving fraction can always be reduced by increasing the number of treatments.
As an example, Fig. 2 shows the ln(S) as a function of the number of treatments when d ϭ 2 Gy, ϭ 1 day (interval between two treatments), ␣ ϭ 0.3 Gy Ϫ1 , and ␣/␤ ϭ 10 Gy (breast cancer). We note that the GL prediction does not depend on the tumor mass, while the UL prediction does depend on it. The tumor's (asymptotic) final mass M is assumed to be 640 g (7) . Since M is a parameter of the West law, it is convenient to define the tumor mass as a fraction of M. Two cases are considered; the dashed line refers to a very small tumor whose mass is 1% of the final one, whereas the dash-dotted line represents a small tumor whose mass is 10% of the final one. It is apparent from the figure that, according to the GL, the tumor cell surviving fraction could be reduced ad libitum simply by increasing the number of fractionated radiation treatments independent of the initial tumor mass (1, 12) . In contrast, the UL establishes a lower limit for the tumor cell surviving fraction that cannot be reduced any further regardless of the total number of treatments. In particular, while in the first half of the treatment only a small discrepancy is observed, in approaching the final standard total dose of 70 Gy (or 35 treatments), the predicted values for ln(S) by the UL is almost 7 orders of magnitude larger than expected by the GL.
In other words, therapeutic control of tumor cell proliferation is poorer if cell regrowth follows the UL instead of the GL, unless the total dose needed for eradication is small enough to be in the range where the GL and UL predict the same value for S. Since such low doses are relevant only for very small tumors, the UL may be able to explain the so-called tumor size effect, in that the tumor control rate achieved with radiation treatments alone declines rapidly for large tumors (T3 or T4 or N2c/N3 in the clinical practice).
To emphasize the different impacts of the GL and UL in the case of standard treatment for tumors with different volumes, we computed P for a different number c of clonogens, i.e. for 10 3 , 10 5 and 10 7 , respectively (Fig. 3 ). As expected, while at low clonogenic cell number c both growth laws predict the same control probability, at an intermediate c therapeutic success is reduced, and there is none for large c. This investigated further by considering the UL and the GL with different treatment schedules. In particular, since clinical experience confirms that highly proliferative tumors are not treated successfully by conventional radiotherapy schedules, we performed simulations that employ non-conventional but widely used radiotherapy schedules. These include hyperfractionation (22) , CHART (23) and hypofractioned regimens (24) , which are known to be more effective in controlling highly proliferative tumors. In Figs. 4, 6 and 8 we present the final surviving fractions (in log scale) as a function of the number of treat- ments for the hypofractionation, hyperfractionation and CHART regimens by considering tumor regrowth according to the GL and UL when the initially observed tumor mass is either 1% or 10% of the asymptotic value (i.e., the maximum size this specific tumor can reach). That yields O r ϭ / ϭ 0.01 and 1. The same schedules were investigated to assess cure probability assuming the tumor mass to be 10% of the final mass and considering clonogenic numbers of 10 3 , 10 5 and 10 7 . Figures 5, 7 and 9 show the results for hypofractionation, hyperfractionation and CHART, respectively.
For the hypofractionation and CHART schedules, we obtain very similar results at small and intermediate values of c, while complete therapeutic success can be achieved for tumors following the UL, provided a larger number of treatments are delivered. In contrast, for the case of hyperfractionation, tumors following the UL cannot be treated satisfactorily if c is large, and there is no advantage with respect to the standard schedule.
DISCUSSION AND CONCLUSIONS
In this paper we compare the tumor cell surviving fractions during a variety of radiotherapy regimens predicted by the Gompertz law (GL) and the Universal growth law (UL). We note that the cell surviving fraction, S, critically depends on the tumor regrowth rate. According to the GL, the tumor cell surviving fraction could be reduced ad libitum simply by increasing the number of fractionated radiation treatments, independent of the initial tumor mass (1, 12) . In contrast, the UL establishes a lower limit for the surviving fraction that is weakly dependent on the clonogenic number and that cannot be reduced further regardless of the total number of treatments. This suggests some important conclusions:
1. Predictions of tumor regrowth by the GL and UL are very similar in the initial part of the treatment only, i.e. up to around 25-30 Gy.
In other words, only if the tumor mass is small enough to be cured by an overall dose delivered by a few treatments will both the GL and the UL predict similar outcomes. Provided that the number of clonogenic cells is small enough, a decrease of about 10 units in the ln(S) would eradicate the tumor and radiotherapy would reach its goal independent of the regrowth curve followed by the tumor. Results are no more satisfactory when larger tumors are irradiated, because, contrary to expectations when relying on the GL, ln(S) does not decrease further, and the clonogenic cell population is not eradicated.
2. The tumor size effect can therefore be understood on the basis of the UL. The dependence of the surviving fraction on the tumor volume was observed by Stanley et al. in 1977 for lung tumors (25) and was re-emphasized by Bentzen et al. (26) and Huchet et al. (27) . Larger tumors are expected to have a greater number of clonogenic cells that would have to be eradicated and that are found in a more hypoxic environment (28) . Both factors affect tumor regrowth and possibly tumor radiosensitivity as well. While the GL is volume-insensitive, the UL accounts for the tumor growth stage and predicts different surviving fractions after radiotherapy. For local control, this is qualitatively in agreement with the results e.g. in breast cancers treated by radiotherapy alone, where the only two significant factors determining treatment outcome (control or failure) were overall dose and tumor size (29) . A more recent analysis of breast cancer (30) shows that, even in the presence of nodal involvement, tumor size does not lose its prognostic significance; rather it maintains its predominant effect on mortality. It is noteworthy that in many cases the dose for 90% local control is strictly related to tumor volume; for instance, in human malignant epithelial tumors, it ranges from 50 Gy for small lesions to 60 Gy for linear dimensions Ͻ2 cm to 75 Gy for large lesions (minimum diameter ഠ4 cm, maximum diameter ഠ6 cm). Finally, rapid tumor regrowth during long (5-8 weeks) radiotherapy treatment is an important clinical parameter (31) .
This re-emphasizes the importance of both early diagnosis and of the gross tumor mass (surgical debulking) prior to radiation treatment, since it implies that radiotherapy may be successful provided that the tumor mass at the onset of treatment is small.
3. When larger tumors are considered, we would expect that, according to GL, the results of therapy depend on the (total) radiation dose delivered, independent of the actual schedule. In contrast, tumor regrowth, according to the UL, is dependent on the radiotherapy schedule.
To qualitatively understand the different behavior of the UL compared to the GL, attention should be paid to the fact that the UL is a power growth law, whereas the GL is a logarithmic law (see the corresponding differential equations). A number n of treatments reduces the number of cells by a factor . Since the regrowth according to the n S 0 UL is power-like, a ''cancellation'' occurs for large n. The GL does not produce this kind of cancellation, and thus cells continue to reduced in number by a factor . n S 0 Clinical experience confirms that highly proliferative tumors are unsatisfactorily treated by conventional radiotherapy schedules. Simulations are therefore proposed by assuming non-conventional radiotherapy schedules such as hyperfractionation (22) , CHART (23) and hypofractioned regimens (24) .
4. It is noteworthy that the application of the linear-quadratic relationship for non-standard fractionation regimens (where radiation doses are delivered twice or three times a day) has been questioned by some authors (32-34) because of the occurrence of incomplete tumor cell repair between radiotherapy fractions. Consequently, Mu et al. (35) suggested that Eq. (1) should be amended by a multiplicative factor G in the d 2 term, thus accounting for the estimated recovery time of sublethal cell damage. We investigated the effect of such an amendment on our predictions. Assuming that, for the case of hyperfractionation, the interval between two treatments is equal to one-third of the standard interval of 24 h, the original coefficient of the d 2 term is multiplied by a factor of 3, we note that (a) the general behavior of ln(S) was largely unaffected, (b) in the case of the UL, the saturation value was reached at approximately the same time and the percentage variation of the ln(S) was less than 10% after 80 treatments, and (c) in the case of the GL, the slope was roughly the same, and the percentage variation of the ln(S) was less than 15% after 80 treatments.
In conclusion, since such corrective adjustments were validated only in other contexts and because there are neither theoretical nor experimental evaluations of the G value for this particular application, and most importantly, since this correction has no major impact on our specific results, we decided to retain the original linear-quadratic formula. Future work will, however, focus on this point more specifically.
Our simulation shows that for tumors following the UL there is a therapeutic advantage in using hypofractionation and CHART schedules, since complete success can be achieved even for large and/or very aggressive tumors (that carry a large clonogenic number c), while hyperfractionation does not improve results compared to a standard radiotherapy schedule. For hypofractionation and CHART, a good agreement between the model and the clinical results is found, since both schedules are used satisfactorily in palliative regimens as well as for treating advanced neoplasms.
In addition to its use for palliative purposes in the case of osseous metastases, hypofractionation has recently been applied curatively, e.g. in brain tumor therapy and in (T1) early-stage lung cancer, due to the promise of sparing organs at risk that is offered by IMRT, stereotactic techniques, cyberknife and tomotherapy.
Regarding hyperfractionation, attention should be paid to the treatment details. The delivery of 0.8 Gy three times a day (''plain'' hyperfractionation) yields significant improvements in local control and survival probability in medium-size oropharingeal tumors (36) . Larger tumors are treated using a variety of schedules including the ''accelerated'' hyperfractionation (1.5-1.6 Gy twice a day), which shows evidence that for some tumors [inflammatory breast cancer (37), head and neck cancer (38) ] standard radiotherapy treatment may be accelerated with benefit. An alternative is using a concomitant boost by adding 1.2 Gy each day in the second and fifth weeks of treatment.
The results of a meta-analysis comparing standard radiation therapy with nonconventional fractionations in head and neck cancers have been published recently (39): generally, the nonconventional fractionations, particularly hyperfractionation and accelerated fractionation, seem to increase both local tumor control and patient survival significantly.
The main concern in increasing the radiation dose is its impact on healthy tissue, which should be spared as much as possible. This goal, however, can be achieved by 3D conformal radiotherapy (3DCRT, IMRT, stereotactic treatment), which allows larger doses to be used. Recently accelerated fractionation and IMRT have been used together in SMART (simultaneous modulated accelerated radiation therapy) (39) and SIB (Simultaneous Integrated Boost) (40) . Investigating all these options is very demanding and should be reserved for follow-up work.
In summary, since there is clinical evidence for better responses of large tumors to some nonconventional schedules such as hypofractionation and CHART, the UL model may be more appropriate to account for the growth of highly proliferating tumors during radiotherapy and may help to explain clinical observations. Up until now, the aforementioned radiotherapy regimens have not been investigated exhaustively with theoretical models, and to our knowledge a comparison between different growing tumors and/ or different radiotherapy schedules is not available. Based on the results presented here, we believe that, much like in the case of the tumor size effect, the Universal law will help us understand experimental and clinical data that cannot be explained by the Gompertz law.
APPENDIX
Let us consider that an in vivo tumor, with N in initial cells, is irradiated at t ϭ 0 with a dose d. This instantaneously produces a surviving fraction
Denoting T as the interval between two treatments, in the interval between 0 and T or, more generally, between jT and ( j ϩ 1)T ( j integer), tumor regrowth (following either the GL or the UL) and different final surviving fractions, S ϭ N n /N in (after n equal treatments), will be predicted. Calculations are described in detail below.
Gompertz Law
According to the Gompertz law, the cell number at a generic time t, N(t), is given by
where N(t 0 ) is the cell number at the initial time and
Therefore, after the first interval T and immediately after the second treatment, the cell number will be
i.e., by Eq. (A1),
At time 2T, immediately after the third dose has been delivered, by Eq. (A2),
and by Eq. (A5), it becomes
where
The general formula, immediately after n treatments, is then
with m ϭ n Ϫ 1 and
Finally, after n equal treatments, the final surviving fraction, S g ϭ N(t)/ N in , for the Gompertz pattern is
where G ϭ f nϪ1 .
West Law
By defining 
The starting point is again given by Eq. (A1). Immediately after the second treatment, at time T,
Resulting from Eq. (A1), the previous equation may be written as /month), and T is typically between 1-2 days. Therefore, for a standard dose of d ϭ 2.5 Gy, ␣ ϭ 0.3 Gy
Ϫ1
and ␣/␤ ϭ 10 Gy (breast cancer), to the first-order approximation, one can write R w (T ) ϭ 1 Ϫ , with ϭ and ഠ ഠ0.4. Equation (A25) is independent of N in and N ϱ and depends on the dose, the interval between treatments, and the growth rate parameter . P asy cannot be improved further by increasing the number of treatments, only by changing the dose and the interval. This is in strong contrast to Gompertz growth where one can (in principle) reduce the final surviving fraction by increasing the number of treatments. Indeed, according to the GL, the final surviving fraction is practically independent of N in and can be decreased continuously by increasing the number of treatments. For the UL, however, there is a dependence on the initial cell number, but there is no possibility at fixed d and T to decrease P asy beyond its asymptotic value.
